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Condensation 
Pandemic influenza vaccine uptake is influenced by maternal 
sociodemographic factors; 2009 A/H1N1 vaccination in pregnancy is not 
associated  with adverse pregnancy outcomes. 
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Abstract 
Objectives 
To describe the uptake of 2009 A/H1N1 Influenza vaccination among 
pregnant women and determine if vaccination was associated with 
adverse pregnancy outcomes. 
 
Study Design 
A retrospective cohort study was performed using booking, Delivery Suite 
and neonatal discharge records from the Coombe Women and Infants 
University Hospital. Singleton deliveries to women pregnant before 
(December 2008-September 2009) and during the pandemic (December 
2009-September 2010) were included. 
Information on vaccination status and type of vaccine was collected on 
admission to the Delivery Suite. Logistic regression analyses were used to 
determine maternal characteristics associated with vaccination. Pregnancy 
outcomes were compared for vaccinated and unvaccinated women, with 
adjustment for differing maternal characteristics. Outcomes included 
vaccination status, preterm birth, size for gestational age, neonatal 
intensive care admission, congenital anomalies and perinatal death. 
 Results 
Of 6894 women pregnant during the pandemic, 2996 (43.5%) reported 
vaccination at delivery. In the early weeks of the vaccination programme 
rates of over 70% were achieved. Of those vaccinated, 246 (8.2%), 1709 
(57.0%) and 1034 (34.5%) were vaccinated in the first, second and third 
trimesters respectively. Vaccination was less likely in younger age groups, 
those who were not in the professional/manager/employer socioeconomic 
group, women from Eastern Europe, Africa and Asia/Middle East, those 
who reported an unplanned pregnancy, women who booked late for 
antenatal care and recipients of publicly-funded obstetric care. Irish 
nationality was associated with reporting vaccination. There was no 
association between vaccination during pregnancy and adverse pregnancy 
outcomes. 
 
Conclusion 
2009 A/H1N1 Influenza vaccination uptake was influenced by maternal 
sociodemographic factors. High vaccination uptake can be achieved in a 
pandemic situation. Future public health campaigns should provide clear 
information on vaccination safety in pregnancy, ensure consistent 
vaccination recommendations from healthcare professionals and provide 
easy access to vaccination in order to optimise uptake rates in subgroups 
of the population who less likely to be vaccinated. There was no 
association between vaccination and adverse pregnancy outcomes. 
 Keywords 
2009 A/H1N1 Influenza; vaccine; pregnancy; uptake; congenital 
anomaly; perinatal death. 
Introduction 
 
Pandemic 2009 A/H1N1 Influenza infection appeared to increase the risk 
of severe maternal morbidity and mortality and was associated with 
adverse pregnancy outcomes including fetal death. (1-4) Previous 
pandemics also demonstrated the risk of serious adverse maternal and 
fetal outcomes. (5) In order to reduce the risk of such adverse outcomes 
vaccinations against pandemic 2009 A/H1N1 Influenza were licensed and 
recommended for use during pregnancy. (6) In Ireland two vaccines were 
commercially available and used in the national immunisation campaign: 
Pandemrix®, an egg-derived vaccine containing thiomersal and the AS03 
adjuvant (DL-α-tocopherol, squalene and polysorbate); and Celvapan®, a 
cell-line-derived, thiomersal free, non-adjuvanted alternative. 
 
Seasonal influenza vaccines have been administered to pregnant women 
since the late 1950s,(7) and the US Advisory Committee on Immunization 
Practices (ACIP) has, since 2004, encouraged pregnant women to be 
vaccinated against seasonal influenza regardless of gestation. (8) Uptake 
rates of 2009 A/H1N1 Influenza vaccine varied internationally during the 
pandemic with studies reporting rates in pregnant women from as low as 
4.7% to as high as 85%. (9-11) Variations in international 
recommendations relating to the optimal timing of vaccination in 
pregnancy, the selection of non-adjuvanted vaccines for pregnant women 
and the need for seasonal influenza vaccination in pregnancy led to media 
commentaries, speculation on vaccine safety and public anxiety. 
 
Available data support the use of the inactivated influenza vaccine during 
all stages of pregnancy, particularly for women with medical conditions 
that may increase the risk of complications. Reassuring 
pharmacoepidemiological studies have indicated that 2009 A/H1N1 
Influenza vaccination is not associated with adverse pregnancy outcomes 
including fetal death, preterm birth and congenital anomalies. (12-17) 
Vaccination may have reduced the risk of influenza-related fetal death 
during the pandemic. (12)  
 
It is essential that extensive data are available on pregnancy outcomes 
after gestational vaccine exposure in order to inform decisions on 
vaccination by pregnant women and health professionals, particularly 
during a pandemic situation. It is also important to study the 
determinants of vaccination uptake in pregnant women in a variety of 
settings, given the regional variations that have been previously reported. 
(18) The main aims of this study are to describe the uptake of 2009 
A/H1N1 Influenza vaccination in pregnant women during the pandemic, to 
determine maternal characteristics associated with vaccine uptake, and to 
determine if there is an association between vaccination and adverse 
pregnancy outcomes.   
Materials and Methods  
The Irish Pandemic Flu Vaccination Programme began in early November 
2009 and ended on the 31st of March 2010. (19) In the initial phase high 
risk groups, including pregnant women, were offered prioritised access to 
the vaccine. 
 
Data on maternal characteristics, medical and obstetric history and 
perinatal outcomes were extracted from electronic hospital records at the 
Coombe Women and Infants University Hospital in Dublin for all singleton 
deliveries during the study period. Data on vaccination status was 
recorded at delivery from the beginning of December 2009. The following 
questions were added to the delivery suite admission form:  
(1) H1N1 vaccine this pregnancy? (Yes/No)  
(2) When given (1st dose) (1st trimester, 2nd trimester, 3rd trimester).  
(3) Vaccine used? (Celvapan 1 dose, Celvapan 2 doses, Pandemrix, 
Unknown) 
 
Preterm and very preterm deliveries were defined as delivery prior to 37 
and 32 weeks gestation respectively. Small for gestational age was 
defined as a birthweight determined to be less than the 10th centile 
customised for maternal weight, height, gestation and infant sex. (20) 
Congenital anomalies were ascertained from Delivery Suite or Neonatal 
Unit electronic records. 
 
Descriptive statistics were used as appropriate to describe maternal 
characteristics of vaccinated and unvaccinated women. Univariable logistic 
regression analyses were used to determine odds ratios and 95% 
confidence intervals for associations between maternal characteristics and 
vaccination. Cases with missing data were excluded from the logistic 
regression analyses. The levels of missing data for each maternal 
characteristic and pregnancy outcome are indicated in Table 1 and Table 
2.  
 Pregnancy outcomes were compared between vaccine-exposed women 
delivering between December 2009 and September 2010 and two 
comparison groups. The first comparison group included women 
delivering from the beginning of December 2009 to the end of September 
2010 who reported that they had not been vaccinated at the time of 
delivery (unvaccinated group). The second comparison group included 
women delivering from the beginning of December 2008 to the end of 
September 2009, representing a time period prior to the mass vaccination 
programme and the main wave of the pandemic (prevaccination group). 
Univariable and multivariable logistic regression analyses were used to 
examine the association between vaccination and adverse perinatal 
outcomes. The multivariable analysis included adjustment for age band at 
delivery, socioeconomic group, region, planning of pregnancy, booking 
gestation, public obstetric care and smoking in pregnancy.  
 
A separate univariable logistic regression analysis was carried out to 
determine if vaccination was associated with congenital anomalies after 
first trimester exposure with comparison to the unvaccinated group. 
Results 
Vaccine Uptake 
Of 6894 women delivering between the beginning of December 2009 and 
the end of the following September, 2996 women (43.5%) reported 
vaccination at delivery. The temporal distribution of vaccination during 
pregnancy is represented in figure 1. Vaccination in the first, second and 
third trimesters was reported by 246 (8.2%), 1709 (57.0%) and 1034 
(34.5%) vaccinated women, respectively. Celvapan® was received by 
1692 (56.5%) women, with approximately half receiving a single dose 
and half receiving two. A single dose of Pandemrix® was received by 698 
(23.3%) women, with a further 606 (20.2%) women unsure of the 
specific vaccine used. 
  
Maternal characteristics of vaccinated and unvaccinated women are 
outlined in table 1. Compared with women in the 25-29 age group, those 
between 30-39 years were more likely to report vaccination. Vaccination 
was most likely in the professional, manager and employer socioeconomic 
group compared to all other groupings. There were regional variations in 
vaccination uptake with women from Eastern Europe less likely to report 
vaccination than those from Western Europe (odds ratio 0.21, 95% 
Confidence Interval 0.17-0.25). Women from Africa and Asia/Middle East 
were also less likely to report vaccination. Irish nationality was associated 
with reporting vaccination (OR 2.25, 95% CI 2.01-2.51). Women who 
reported an unplanned pregnancy were less likely to be vaccinated. Those 
booking after 20 weeks were less likely to be vaccinated (OR 0.49, 95% 
CI 0.39-0.62) compared to those booking between 12 and 20 weeks’ 
gestation. Women who received privately-funded obstetric care were 
more likely to report vaccination (OR 1.43, 95% CI 1.25-1.63). 
 
Maternal and perinatal outcomes for the vaccinated and unvaccinated 
groups are compared in table 2. Adverse perinatal outcomes did not 
appear to differ significantly between the vaccinated group and the two 
comparison groups. In the unadjusted analyses, vaccinated women were 
less likely to have an elective caesarean section than the unvaccinated 
group. Preterm birth (<37 and <32 weeks) was also less likely in the 
vaccinated women. Adjustment for maternal characteristics that differed 
significantly between the vaccinated and unvaccinated groups with 
multivariable logistic regression analyses did not alter the results. 
 
There were nine congenital anomalies among 246 pregnancies where 
women reported vaccination in the first trimester and 110 among 3897 
pregnancies in unvaccinated women (3.7% vs. 2.8%; OR 1.31, 95% CI 
0.65-2.61). The congenital anomalies recorded for the nine neonates 
were: duplication of left ureter (history of duplicate kidneys in siblings), 
atrophic right kidney (maternal history of atrophic kidney also), 
unspecified chromosomal anomaly, mild pyelectasis on antenatal 
ultrasound, subcutaneous dermoid cyst, hydronephrosis on antenatal 
ultrasound, bilateral hydrocele, albinism and cardiomyopathy (maternal 
cardiomyopathy also). 
 
Comment 
Main Findings 
This study demonstrated that 42% of women delivering between 
December 2009 and September 2010 had received at least one dose of 
pandemic 2009 A/H1N1 Influenza vaccine, with vaccination rates of over 
70% in the weeks after the initiation of the vaccination programme. Of 
the women with known vaccine type, the majority (70.7%) received the 
cell-line-derived, thiomersal free, non-adjuvanted product Celvapan®. 
Women who were less likely to be vaccinated included those in younger 
age groups, those who were not in the professional/manager/employer 
socioeconomic group, women from Eastern Europe, Africa and Asia/Middle 
East, women who booked late for antenatal care, those who reported an 
unplanned pregnancy and those who received publicly-funded obstetric 
care. Vaccination was not associated with adverse pregnancy outcomes. 
 Strengths and Limitations 
This study was conducted in a large tertiary referral maternity hospital 
that delivers approximately 9,000 babies annually. Data on maternal 
characteristics, medical history, vaccination status and pregnancy 
outcomes were routinely collected by midwives using structured 
computer-guided and paper questionnaires. Data were available on a 
diverse group of women from a broad range of socioeconomic groupings. 
Virtually all deliveries during the study period were included in the 
analysis, reducing the risk of selection bias. This study also provided 
information on both adjuvanted and unadjuvanted vaccines. The study 
results are likely to be generalisable to women receiving antenatal care in 
similar hospital settings worldwide, though international variations in 
vaccine uptake are likely. 
 
This study was limited by the inclusion of only one maternity hospital. 
Current constraints imposed by the Irish Data Protection Act precluded a 
planned study including the three main Dublin maternity hospitals which 
deliver 4 in 10 Irish babies. Pregnancy outcomes were ascertained after 
information on vaccination status was collected, this may have potentially 
led to biased assessment of outcomes, however there is no evidence to 
suggest that this occurred. The study was also limited by the constraint of 
ascertainment of vaccination status at delivery as this prevented any 
analysis of the relationship between vaccination and early pregnancy loss. 
Reliance on maternal self-report of vaccination status, vaccine used and 
timing of vaccination is a potential limitation, however the high profile 
nature of the pandemic vaccination recommendations meant that most 
women knew this information. Congenital anomalies were ascertained 
from routine hospital records up to the time of hospital discharge. There 
was limited recording of clinical details of anomalies and it is possible that 
misclassification led to an underestimation of congenital anomalies for all 
neonates. Although multivariable logistic regression was used to adjust 
for differing maternal characteristics between the comparison groups, it is 
possible that residual confounding remained. This residual confounding 
may have explained the apparent differences in the elective caesarean 
section rate between the vaccinated and unvaccinated groups.  
 
Interpretation 
There are a number of factors that may have an impact on vaccination 
uptake rates in the pregnant population. Maternal characteristics 
associated with vaccination include working outside the home, being 
multiparous and having a higher level of education. (21) Other factors 
include the safety concerns of both patients and healthcare workers and 
also a lack of recommendation of vaccination by medical 
professionals.(22) A US survey of postpartum women, which reported a 
vaccination rate of 34%, indicated that the strongest determinants of 
vaccination were awareness of vaccine safety and health professional 
recommendations. (23) Some studies identified that Pandemic 2009 
A/H1N1 Influenza vaccination was actually offered to a minority of women 
during pregnancy. (24, 25) Maternal co-morbidities have also been 
demonstrated to affect the likelihood of vaccination along with regional 
variations in uptake. (18) 
 
Several similar studies in a variety of international settings have reported 
uptake rates in pregnancy below 15%. (10, 21, 22, 26) Vaccine 
availability issues early in the pandemic may have reduced uptake in 
some studies. Higher rates of 37 to 85% have been reported in other 
studies from the US and UK. (27-29) In a Dutch online survey with a 
20.6% response rate, 63% of pregnant women reported vaccination. (30) 
An EU survey reported that for pregnant women, Ireland had the second 
highest vaccination coverage at 32% after the Netherlands at 58%. (31) 
In line with the findings of this study, vaccination was much less likely in 
Eastern European countries. Low uptake of the vaccine in pregnancy has 
also been reported in an Australian study. (32) 
The higher estimates from some patient surveys may be caused by 
sampling bias. Uptake rates will also vary between studies depending on 
the time period included. In this study, vaccination rates of up to 70% 
were achieved in women delivering in the weeks after the initiation of the 
vaccination campaign. These uptake rates may be explained by clear 
public health messages given in antenatal clinics along with specific 
vaccination clinics run in the hospital to coincide with antenatal clinics. 
Vaccination was also available through national vaccination programmes 
run in the community by public health services.  
 
This study adds to previous findings of regional variations in vaccination 
uptake. (18, 31) Maternal characteristics associated with not being 
vaccinated were similar in several international studies. A Canadian study 
also reported variations in vaccination rates related to maternal age, 
socio-economic status and late booking.(33) A French study had similar 
findings with higher vaccination rates in women who were older, 
employed and born in France.(34)  
 
Previous studies support the current findings of no association between 
pandemic 2009 A/H1N1 Influenza vaccination in pregnancy and adverse 
pregnancy outcomes including fetal death, preterm birth and congenital 
anomalies. (12-17) One previous study noted an association between 
vaccination and a marginal risk reduction for caesarean section. (17) 
 
Conclusion 
This study demonstrates that high influenza vaccine uptake rates can be 
achieved for pregnant women in a pandemic situation. Future public 
health campaigns should provide clear information on vaccination safety 
in pregnancy, ensure consistent advice and vaccination recommendations 
from healthcare professionals and provide easy access to vaccination e.g. 
through integration with antenatal care to optimise uptake rates in 
subgroups of the population who less likely to be vaccinated. 
 Reassuring data from geographically diverse locations on the relationship 
between maternal vaccination and pregnancy outcomes will aid future 
vaccination campaigns. This wealth of safety data will attenuate public 
uncertainty about vaccine safety in pregnancy. The available data may 
also improve uptake rates in pregnant women in future pandemics. 
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 Table 1. Maternal Characteristics among vaccinated and unvaccinated 
Pregnancies  
  N=6894 
Vaccinated                     
n=2996 
(43.5%) 
Unvaccinated                  
n=3898 
(56.5%) OR 95% CI 
Age at delivery 6894     
 <20 years  97 (37.7) 160 (62.3) 0.92 0.70-1.21 
 20-24 years  353 (40.3) 522 (59.7) 1.03 0.87-1.22 
 25-29 years  686 (39.6) 1045 (60.4) 1 - 
 30-34 years  1015 (44.9) 1248 (55.1) 1.24 1.09-1.41 
 35-39 years  719 (48.8) 753 (51.2) 1.45 1.26-1.67 
 >40 years  126 (42.6) 170 (57.4) 1.13 0.88-1.45 
Socioeconomic group 6888     
 Home duties  481 (37.1) 815 (62.9) 0.61 0.52-0.70 
 Professional/Manager
 /Employer  910 (49.3) 934 (50.7) 
1 - 
 Non-Manual  1115 (44.2) 1406 (55.8) 0.81 0.72-0.92 
 Manual  110 (34.4) 210 (65.6) 0.54 0.42-0.69 
 Unemployed  240 (42.9) 319 (57.1) 0.77 0.64-0.93 
 Non-classifiable  140 (40.2) 208 (59.8) 0.69 0.55-0.87 
Nationality- Irish 6838     
 Yes  2352 (49.2) 2431 (50.8) 1 - 
 No  618 (30.1) 1437 (69.9) 0.44 0.40-0.49 
Region 6838     
 Western Europe  2460 (48.6) 2598 (51.4) 1 - 
 Eastern Europe  144 (16.6) 724 (83.4) 0.21 0.17-0.25 
 Africa  128 (39.1) 199 (60.9) 0.68 0.54-0.85 
 South America  16 (50.0) 16 (50.0) 1.05 0.53-2.11 
 North America  14 (53.8) 12 (46.2) 1.23 0.57-2.67 
 Asia/Middle East  201 (39.4) 309 (60.6) 0.69 0.57-0.83 
 Australia & New 
 Zealand  7 (41.2) 10 (58.8) 
0.74 0.28-1.94 
Married 6792     
 Yes  1815 (43.4) 2365 (56.6) 1 - 
 No  1140 (43.6) 1472 (56.4) 1.00 0.91-1.11 
Nulliparous 6894     
 Yes  1248 (42.8) 1669 (57.2) 1 - 
 No  1748 (44.0) 2229 (56.0) 1.04 0.95-1.15 
Planned pregnancy 6850     
 Yes  2055 (44.6) 2557 (55.4) 1 - 
 No  934 (41.7) 1304 (58.3) 0.89 0.80-0.99 
Booking gestation (weeks) 6832     
 < 12 weeks  1317 (46.9) 1493 (53.1) 1.18 1.06-1.30 
 12 - 20 weeks  1547 (42.8) 2065 (57.2) 1 - 
 > 20 weeks  110 (26.8) 300 (73.2) 0.49 0.39-0.62 
Publicly-funded obstetric 
care 6894   
  
 Yes  2444 (43.5) 3366 (57.9) 1 - 
 No  552 (50.9) 532 (49.1) 1.43 1.25-1.63 
Smoked During Pregnancy 6891     
 No  2527 (43.6) 3270 (56.4) 1 - 
 Yes  469 (42.9) 625 (57.1) 0.97 0.85-1.10 
 
Table 2. Maternal & Perinatal Outcomes among Vaccinated and Unvaccinated Pregnancies 
  n=13938 
Vaccinated                     
n=2996 
Unvaccinated                  
n=3898  
Pre-
vaccination 
n=7044  OR1 95% CI OR2 95% CI 
Mode of Delivery 13938        
 SVD  1768 (59.0) 2220 (57.0) 4105 (58.3) 1 - 1 - 
 Elective LSCS  208 (6.9) 496 (12.7) 760 (10.8) 0.53 0.44-0.63 0.64 0.54-0.75 
 Emergency LSCS  420 (14.0) 548 (14.1) 919 (13.0) 0.96 0.83-1.11 1.06 0.93-1.21 
 Forceps  247 (8.2) 296 (7.6) 522 (7.4) 1.05 0.88-1.26 1.10 0.93-1.29 
 Ventouse  353 (11.8) 338 (8.7) 738 (10.5) 1.31 1.12-1.54 1.11 0.97-1.28 
Preterm birth < 37 weeks 13824 141 (4.7) 252 (6.5) 371 (5.3) 0.71 0.58-0.88 0.89 0.73-1.08 
Spontaneous Birth < 37 weeks 13824 73 (2.5) 127 (3.3) 198 (2.8) 0.74 0.55-0.99 0.86 0.66-1.13 
Very preterm birth < 32 weeks 13824 26 (0.9) 60 (1.6) 73 (1.0) 0.56 0.35-0.89 0.84 0.53-1.31 
Spontaneous Birth < 32 weeks 13824 15 (0.5) 25 (0.6) 30 (0.4) 0.78 0.41-1.48 1.17 0.63-2.19 
Small for gestational age < 10th 
centile† 
13824 368 (12.4) 485 (12.6) 862 (12.3) 0.98 0.85-1.13 1.00 0.88-1.14 
Apgar score <3 at 1 minute 13911 27 (0.9) 42 (1.1) 57 (0.8) 0.83 0.51-1.35 1.11 0.70-1.76 
Apgar score <7 at 5 minutes 13853 21 (0.7) 33 (0.9) 50 (0.7) 0.82 0.47-1.43 0.98 0.59-1.64 
Admitted to neonatal unit 13938 507 (16.9) 652 (16.7) 942 (13.4) 1.01 0.89-1.15 1.32 1.17-1.48 
Congenital anomaly 13938 66 (2.2) 110 (2.8) 181 (2.6) 0.78 0.57-1.05 0.85 0.64-1.14 
Perinatal Death* 13938 11 (0.4) 22 (0.6) 39 (0.6) 0.65 0.31-1.34 0.66 0.34-1.29 
 
1 Vaccinated versus unvaccinated (Unadjusted odds ratio) 
2 Vaccinated versus pre-vaccination (Unadjusted odds ratio) 
† Birth weight centiles were calculated using GROW-Centile, a customised weight centile calculator 
* includes stillbirths and neonatal deaths. Stillbirth was defined as delivery of a baby showing no signs of life at or 
after 24 weeks gestation. Neonatal death was defined as the death of a baby within the first seven days of life. 
 
